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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.011Prostate cancer (CaP) progresses to a castration-resistant state assisted by multifold molecular changes,
most of which involve activation of the androgen receptor (AR). Having previously demonstrated the
importance of the Lin28/let-7/Myc axis in CaP, we tested the hypothesis that Lin28 is overexpressed in
CaP and that it activates AR and promotes growth of CaP cells. We analyzed human clinical CaP samples for
the expression of Lin28 by quantitative real-time RT-PCR, Western blot analysis, and IHC. Growth char-
acteristics of CaP cell lines transiently and stably expressing Lin28 were examined. The clonogenic ability
of CaP cells expressing Lin28 was determined by colony formation and soft agar assays. Increase in
expression of AR and subsequent increase in transcription of AR-target genes were analyzed by quanti-
tative real-time RT-PCR, luciferase assays, and ELISA. LNCaP cells stably expressing Lin28 were injected
into nude mice, and tumorigenesis was monitored. We found that Lin28 is overexpressed in clinical CaP
compared to benign prostates. Overexpression of Lin28 enhanced, while down-regulation reduced,
growth of CaP cells. Lin28 enhanced the ability of CaP cells to form colonies in anchorage-dependent and
anchorage-independent conditions. LNCaP cells stably expressing Lin28 exhibited signiﬁcantly higher
tumorigenic ability in vivo. Lin28 induced expression of the AR and its target genes such as PSA and
NKX3.1. Collectively, our ﬁndings demonstrate a novel role for Lin28 in CaP development and activation of
the AR axis. (Am J Pathol 2013, 183: 288e295; http://dx.doi.org/10.1016/j.ajpath.2013.03.011)Supported, in part, by NIH/National Cancer Institute grants CA140468,
CA118887, and Department of Defense grant PCRP PC080538, the US
Department of Veterans Affairs, the Ofﬁce of Research and Development
(Veteran Affairs Merits I01 BX000526), and resources from the Veteran
Affairs Northern California Health Care System (Sacramento) (to A.C.G.),
and Department of Defense grant PCRP PC100502 (N.N.).Prostate cancer (CaP) remains one of the cancers with high
incidence and mortality rates among men in the United
States. Progression of CaP to castration resistance is the
major challenge facing efforts to develop effective therapies
against CaP. Castration-resistant prostate cancer evades
androgen ablation by activating androgen receptor (AR)e
dependent signaling through alternative mechanisms. Pre-
vious reports have shown that castration-resistant prostate
cancer may evolve by suppression of tumor-suppressor
genes and miRNAs, activation of potential oncogenes,
overexpression of the AR, and activation of other signaling
cascades.1 miRNAs are small RNAs that regulate gene
expression by binding to the untranslated regions of target
mRNAs and inhibiting their translation. The let-7 family of
miRNAs is regulated by Lin28 and Lin28B, two homologues
of the heterochronic gene lin-28 in Caenorhabditis elegans.2
The let-7 family miRNAs are tumor suppressors and are
implicated as prognostic factors in a multitude of cancers.3e5stigative Pathology.
.Hence, Lin28/Lin28B, which inhibit maturation of let-7
miRNAs, may be potential oncogenes in several malignan-
cies. Our previous studies indicated that the Lin28/let-7
double-negative feedback loop regulates AR-dependent
signaling in human CaP and that let-7 miRNA expression
is suppressed in most cases of primary and castration-
resistant CaP.6,7
Lin28, a highly conserved RNA-binding protein and
a master regulator of let-7 miRNA processing, is overex-
pressed in primary human tumors8,9 and is postulated to be
one of the embryonic stem cell factors that promote onco-
genesis and proliferation of cancer cells.10 Lin28 binds to
Lin28 Promotes Growth of CaP Cellsthe terminal loops of the precursors of let-7 family miRNAs
and blocks their processing into mature miRNAs.11,12 Lin28
also derepresses c-Myc by repressing let-7, and c-Myc
activates transcription of Lin28.13,14 This Lin28/let-7/c-Myc
loop may play an important role in the deregulated miRNA
expression signature observed in many cancers.15
In this study, we hypothesized that Lin28 may function as
a prosurvival factor inCaP.To test this hypothesis,we analyzed
expression levels of Lin28 in human CaP samples and found
that Lin28 levels are up-regulated in CaP.We expressed Lin28
transiently and constitutively in LNCaP human CaP cells
and found that Lin28 enhances growth, invasion, and soft
agar colony formation. Expression of Lin28 also led to up-
regulation of expression of AR and its target genes. Constitu-
tive expression of Lin28 also promoted tumorigenicity of
LNCaP cells in nude mice. Knockdown of endogenous
Lin28 inhibited expression of the AR and led to reduced levels
of cell growth. Taken together, these data demonstrate the
functional importance of Lin28 in human CaP.
Materials and Methods
Cell Lines, Antibodies, and Other Reagents
LNCaP, C4-2B, and DU145 prostate cancer cell lines and the
PZ-HPV7 normal prostate epithelial cell line were purchased
from ATCC (Manassas, VA). LNCaP-S17 and LNCaP-IL6
cell lines were described previously.16 LNCaP cells stably
expressing Lin28 (LN-Lin28) were generated by transfection
of pLKO.1-Lin28 (Open Biosystems, Pittsburgh, PA)
into LNCaP cells. Expression of Lin28 in the stable trans-
fectants was conﬁrmed by Western blot analysis. LNCaP
cells expressing Tet-inducible Lin28 (LN/TR/Lin28) were
generated according to the manufacturer’s instructions using
the ViraPower Lentiviral Transduction System (Invitrogen,
Grand Island, NY). Inducible expression of Lin28 was
conﬁrmed by Western blot analysis after induction with 0.5
mg/mL doxycycline (Sigma, St. Louis, MO). Antibodies
against AR and tubulin (AR-441 and T5168) were from Santa
Cruz Biotechnologies (Santa Cruz, CA), and Lin28 anti-
bodies (Ab-71415) were from Abcam (San Francisco, CA).
Western Blot Analysis
Cells were lysed in high salt buffer containing 50 mmol/L
HEPES (pH 7.9), 250 mmol/L NaCl, 1 mmol/L EDTA, 1%
NP-40, 1 mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/L
Na vanadate, 1 mmol/L NaF, and protease inhibitors (Roche,
Indianapolis, IN), as previously described.6 Total protein was
estimated using the Coomassie Protein Assay Reagent (Pierce,
Rockford, IL). Equal amounts of protein were loaded onto 10%
SDS-PAGE and transferred to nitrocellulose membranes. The
membranes were blocked with 5% nonfat milk in PBST (1
PBS þ 0.1% Tween-20) and probed with primary antibodies
in 1% bovine serum albumin. The signal was detected by
enhanced chemiluminescence (GE Healthcare, Waukesha, WI)The American Journal of Pathology - ajp.amjpathol.orgafter incubation with the appropriate horseradish peroxidasee
conjugated secondary antibodies.
Real-Time RT-qPCR
Total RNAs were extracted using TRIzol (Invitrogen) and
were subjected to digestion with RNase-free RQ1 DNase
(Promega, Madison, WI) before reverse transcription. The
resultant cDNAs were subjected to real-time quantitative
RT-PCR (RT-qPCR) using SsoFast Eva Green supermix
(Bio-Rad, Hercules, CA), as described previously.7 Each
reaction was normalized by coampliﬁcation of actin. Trip-
licates of samples were run on default settings of a Bio-Rad
CFX-96 real-time cycler. Sequences of primers used have
been published previously.6,7,17
Clonogenic Assays
Anchorage-dependent clonogenic ability assays were per-
formed as described previously.18 At the end of the exper-
iment, colonies were ﬁxed with methanol, stained with
crystal violet, and counted.
Soft-Agar Colony Formation Assays
Anchorage-independent colony formation assays were per-
formed as described previously.7 At the end of the experi-
ment, colonies were stained with 0.005% crystal violet and
counted.
Cell Growth Assays
PZ-HPV7, LNCaP, C4-2B, DU145, LNCaP-S17, LN-
Lin28, and LN/TR/Lin28 cells were plated in 12-well plates
in triplicate, and viable cell numbers were determined at 0,
24, and 48 hours using a Coulter cell counter (Beckman
Coulter, Brea, CA).
Invasion Assays
Boyden chamber invasion assays were performed as
described previously.19 Brieﬂy, 1  105 cells were plated in
deﬁned medium on Matrigel-coated cell culture inserts (BD
Biosciences, San Jose, CA), with complete medium in the
lower chamber. After incubation at 37C for 48 hours, unin-
vaded cells were scraped off, the membrane inserts were
washed and stained, and invaded cells on the lower surface
were counted.
Animals
Male nude mice (aged 6 to 8 weeks) were maintained in the
Animal Facility at University of California (UC)DavisMedical
Center (Sacramento). All experimental procedures using
animals were approved by the Institutional Animal Care and
Use Committee of UC Davis. Cells (2  106 per ﬂank) were
injected s.c. into both ﬂanks, and tumors were allowed to grow.289
Figure 1 Lin28 is overexpressed in human prostate cancer. A: RT-qPCR
analysis of Lin28 expression in 10 paired benign and tumor CaP tissues.
Data are presented as means  SD of two experiments performed in trip-
licate. *P  0.05. Lin28 mRNA expression levels were higher in cancer
tissues compared to matched benign tissues. B: Western blot analysis of
Lin28 expression in 42 paired benign (B) and tumor (T) samples. Repre-
sentative Western blot analysis is shown. The table summarizes the results
of Lin28 protein expression levels in the data set. C: IHC analysis of Lin28
expression in benign and cancer CaP tissues. Brown staining represents
positive staining for expression of Lin28. Original magniﬁcation, 200.
Tummala et alTumors were measured twice weekly. At the end of the
experiments, tumors were excised and sera were collected for
measurement of prostate-speciﬁc antigen (PSA).
Measurement of PSA
PSA levels were measured in the culture supernatants and
mouse sera using enzyme-linked immunosorbent assay
(ELISA; United Biotech Inc., Mountain View, CA),
according to the manufacturer’s instructions.
Human CaP Specimens
The paired benign and tumor prostate tissues used for RT-
qPCR of Lin28 were previously described.20 The protein
extracts fromhuman prostate specimens used forWestern blot
analysis of Lin28 were previously described.21,22 Immuno-
histochemical (IHC) staining of Lin28 was performed using
a TMA PROS-006 obtained from UC Davis Comprehensive
Cancer Center Biorepository. Staining was performed by the
pathology core facility, and staining intensity was scored on
a scale of 0 to 3 (0, negative; 1, weak; 2, strong; and 3, very
strong). Brown color was considered positive staining for
Lin28, and nuclear staining was denoted by blue color.
Statistical Analysis
Data are shown as means  SD. Multiple-group comparison
was performed by one-way analysis of variance. P  0.05
was considered signiﬁcant.
Results
Lin28 Is Overexpressed in Clinical Prostate Cancer
Specimens
To determine the relative levels of expression of Lin28 in
human CaP compared to benign prostates, we examined
RNAs from 10 paired benign and tumor human CaP samples
by RT-qPCR. Expression levels of Lin28 were found to be
signiﬁcantly elevated in 9 of 10 pairs of matched benign and
tumor prostate specimens (Figure 1A). Extracts from archived
human clinical prostatectomy specimens were also examined
for expression of Lin28 byWestern blot analysis. The data set
contains 42 matched benign and cancer specimens, and
expression levels of Lin28 were higher in cancer tissues (86%
positive and 14% negative) compared to matched benign
prostate tissues (47% positive and 53%negative) (Figure 1B).
IHC was performed in formalin-ﬁxed, parafﬁn-embedded
prostate clinical specimens in a TMA PROS-006 (UC Davis
Cancer Center Biorepository) with Lin28 antibody (Ab-
7141523), and staining intensitywas scored over a scale of 0 to
3 (0, negative; 1, weak; 2, strong; and 3, very strong). Lin28
was expressed in both nuclear and cytoplasmic compart-
ments, with no signiﬁcant differences in the pattern of
expression with increasing Gleason grade (Figure 1C). We
observed strong nuclear staining of Lin28 in benign prostate290tissues almost exclusively in the basal cell layer, with no
staining in the luminal epithelial compartment. In contrast, an
apparent shift from mostly nuclear localization in benign
prostate to a nuclear þ cytoplasmic or mostly cytoplasmic
localization appeared to occur in CaP (Table 1). Docu-
mentation of staining speciﬁcity for IHC is presented in
Supplemental Figure S1.ajp.amjpathol.org - The American Journal of Pathology
Table 1 Summary of IHC Results for Lin28 in TMA PROS-006
No. of cores
Benign
(n Z 19)
Gleason 6
(n Z 29)
Gleason 7-8
(n Z 26)
Nuclear alone 12 (63) 1 (3) 0 (0)
Nuclear þ cytoplasmic 4 (21) 17 (58) 11 (42)
Cytoplasmic alone 3 (15) 11 (38) 15 (57)
Data are given as number (percentage).
Figure 2 Lin28 promotes growth of CaP cells. A: LNCaP, PZ-HPV7, C4-
2B, DU145, LNCaP-S17, and LNCaP-IL6 cells were transfected with empty
vector or pLKO.1-Lin28, and growth was monitored at 0, 24, and 48 hours.
Lin28-enhanced growth rates of all cell lines tested. B: LNCaP cells stably
expressing Lin28 (LN-Lin28), and control (Con) LN-neo cells were plated in
media containing complete FBS and growth was monitored at 0, 24, 48, and
72 hours. Left panel: Lin28 enhanced the growth of LNCaP cells. Right
panel: The expression levels of Lin28 in LN-Lin28 and LN-neo cells. C: Left
panel: C4-2B cells stably expressing Lin28 (C4-2B-Lin28), and control
C4-2B-neo cells were plated in media containing complete FBS and growth
was monitored at 0, 24, 48, and 72 hours. Right panel: The expression
levels of Lin28 in C4-2B-Lin28 and C4-2B-neo cells. Data are presented as
means  SD of three experiments performed in triplicate.
Lin28 Promotes Growth of CaP CellsLin28 Enhances Growth of Prostate Cancer Cells
To test whether Lin28 activates a prosurvival mechanism in
CaP cells, we transfected Lin28 into a panel of CaP cell
lines (LNCaP, C4-2B, DU145, LNCaP-S17, and LNCaP-
IL6) and a nontumorigenic prostate epithelial cell line (PZ-
HPV7). Lin28 enhanced the growth rate of all CaP cell lines
tested (Figure 2A). To conﬁrm these results, LNCaP and
C4-2B cells stably expressing Lin28 (LN-Lin28 and C4-2B-
Lin28) were generated, and growth characteristics were
examined. Compared to control LNCaP cells expressing the
empty vector (LN-neo and C4-2B-neo), LN-Lin28 and C4-
2B-Lin28 cells exhibited faster growth rates (Figure 2, B
and C), suggesting that Lin28 promotes growth of prostate
cancer cells in vitro.
To examine the effects of down-regulation of Lin28 on
CaP growth, lentiviral vector-driven shRNA against Lin28
(Open Biosystems) was transfected into C4-2B cells, and
cell growth was monitored. C4-2B cells transfected with
Lin28 shRNA exhibited lower rates of growth, compared to
cells transfected with shRNA against enhanced green ﬂuo-
rescent protein (EGFP) (Figure 3). Down-regulation of
Lin28 was conﬁrmed by Western blot analysis (Figure 3).
These data demonstrated that down-regulation of Lin28
reduces proliferation of CaP cells.
Lin28 Increases Clonogenic Ability of LNCaP Cells
To test whether Lin28 inﬂuences the ability of CaP cells to
form colonies in anchorage-dependent and anchorage-
independent conditions, we performed clonogenic assays
by transiently transfecting Lin28 into C4-2B and LNCaP-
S17 cells. The results showed that the number of colonies
formed by C4-2B cells expressing Lin28 was 356  14,
whereas the number of colonies formed by control C4-2B
cells was 182  10 (Figure 4A). Similarly, the number of
colonies formed by LNCaP-S17 cells expressing Lin28 was
392  19, whereas the number of colonies formed by
control LNCaP-S17 cells was 212  15 (Figure 4A). These
experiments were conﬁrmed using LN-Lin28 cells (LNCaP
cells stably expressing Lin28), which exhibited a 3.4-fold
increase in colony-forming ability compared to LN-neo
cells (228  21 versus 67  13 colonies) (Figure 4B).
These results were also conﬁrmed using LN/TR/Lin28 cells
(LNCaP cells expressing tet-inducible Lin28), which
exhibited higher clonogenic ability compared to control LN/
TR/Con cells upon doxycycline induction (Figure 4B).
Collectively, these ﬁndings suggest that Lin28 enhancesThe American Journal of Pathology - ajp.amjpathol.orgthe ability of prostate cancer cells to form colonies in
anchorage-dependent conditions.
To further test whether Lin28 regulates anchorage-
independent growth of CaP cells, we performed soft agar
colony formation assays with C4-2B and LNCaP-S17 cells
transfected with Lin28, as described in Materials and
Methods. The results showed that Lin28 promoted the
growth of both C4-2B (Figure 3C) and LNCaP-S17
(Figure 4C) cells in soft agar, compared to control C4-2B or
LNCaP-S17 cells transfected with the empty vector. Simi-
larly, LN-Lin28 cells exhibited signiﬁcantly better ability to
grow in soft agar, whereas control LN-neo cells failed to291
Figure 3 Down-regulation of endogenous Lin28 suppresses CaP cell
growth. C4-2B cells were transfected with shRNA against Lin28, and growth
was measured in media containing complete FBS. Left panel: Growth of
C4-2B cells was abrogated with down-regulation of Lin28. Right panel:
Reduced expression of Lin28 protein after transfection with shRNA. Data
are presented as means  SD of three experiments performed in triplicate.
Tummala et algrow in soft agar (Figure 4D), demonstrating that Lin28
confers soft agar colony-forming ability on CaP cells.Lin28 Increases Invasiveness of LNCaP Cells
To test whether Lin28 regulates the ability of CaP cells to
invade through Matrigel in vitro, we performed Boyden
chamber invasion assays using LN-Lin28 and control LN-
neo cells. Cells were plated on Matrigel in the upper
compartment of the Boyden chamber and allowed to invade
toward the lower compartment ﬁlled with complete medium
containing complete fetal bovine serum (FBS) or charcoal
dextran-stripped FBS (CS-FBS). The number of LN-Lin28
cells invading through Matrigel in FBS-containing
medium was 118  10, whereas the number of control
cells invading through Matrigel was 60  5 (Figure 4D).
Similarly, the number of LN-Lin28 cells invading through
Matrigel in CS-FBSecontaining medium was 54  6,
whereas the number of control cells was 4  2 (Figure 4D),
indicating that Lin28 induces invasion of CaP cells through
basement membrane in vitro.Figure 4 Lin28 promotes clonogenic ability of CaP cells. A: C4-2B and
LNCaP-S17 cells were transfected with empty vector or pLKO.1-Lin28, and
anchorage-dependent clonogenic assays were performed. Lin28 enhanced
the colony-forming ability of both C4-2B and LNCaP-S17 cells. B: LN-Lin28
and control (Con) LN-neo cells were subjected to clonogenic assays. Lin28-
expressing LNCaP cells exhibited higher clonogenic ability compared to
control cells. LN/TR/Lin28 (LNCaP cells expressing Lin28 under a Tet-
inducible promoter) and LN/TR/Con cells were subjected to clonogenic
assays in media containing either complete FBS or CS-FBS. Induction of Lin28
expression by doxycycline (DOX) enhanced colony formation of LN/TR/Lin28
cells compared to control cells. C: C4-2B and LNCaP-S17 cells were transfected
with empty vector or pLKO.1-Lin28 and subjected to anchorage-independent
soft agar colony formation assays. Lin28 expression increased the number of
colonies formed in soft agar by both cell lines. D: Left panel: LN-Lin28 and
control LN-neo cells were subjected to soft agar assays. LN-Lin28 cells were
able to form more colonies in soft agar compared to LN-neo cells. Right
panel: Lin28 increases invasiveness of CaP cells. LN-Lin28 and LN-neo cells
were subjected to Boyden chamber invasion assays. Inset: Representative
images of invading cells. Data are presented as means  SD of three exper-
iments performed in triplicate. *P  0.05.Lin28 Promotes Tumorigenicity of CaP Cells in Vivo
To test whether the growth-promoting effect of Lin28 can
be recapitulated in vivo, we injected 2  106 LN-Lin28 cells
or control LN-neo cells s.c. into each ﬂank of male nude
mice and monitored their tumorigenic ability. Tumors were
measured twice weekly, and serum samples were collected
at the end of the experiment to conﬁrm that the tumor cells
secreted PSA. We found that mice injected with LN-Lin28
cells exhibited signiﬁcantly higher rates of incidence and
growth of tumors compared to control LN-neo cells, which
formed slow-growing tumors (Figure 5A). Higher levels of
secretion of PSA were observed in mice bearing tumors
expressing Lin28 compared to mice bearing control tumors
(Figure 5B). Total RNA and protein extracts from the
tumors were examined for expression levels of Lin28 and
AR. Lin28 was highly expressed in the tumors, which was
correlated positively with expression levels of AR
(Figure 5C), indicating that higher expression of Lin28292enhances expression of AR and promotes tumor growth of
LNCaP human CaP cells in vivo.
Lin28 Activates Androgen Receptor Signaling Axis
As we previously reported that hsa-let-7c, an miRNA
regulated by Lin28, suppressed expression of the AR,6 we
examined whether Lin28 regulates expression of the AR.
We transfected a luciferase reporter vector driven by the
full-length promoter of AR (pGL4-AR-Prom-Luc) into LN-
neo and LN-Lin28 cells and performed luciferase assays.
LN-Lin28 cells exhibited higher levels of activation of AR
promoter compared to control cells (Figure 6A), indicating
that Lin28 may activate transcription of the AR gene. Next,
we analyzed the mRNA levels of AR in LN-neo and LN-
Lin28 cells and found that LN-Lin28 cells exhibited
signiﬁcantly higher levels of AR mRNA (Figure 6A).ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Lin28 promotes tumor growth of CaP xenografts. A: Cells (2 
106 perﬂank of LN-Lin28 or LN-neo)were injected s.c. into bothﬂanks ofmale
nude mice, and tumor growth was monitored. B: Secretion of PSA by the CaP
xenografts was measured in the mouse serum samples. Tumors expressing
Lin28 secreted more PSA compared to the control tumors. C: Higher expres-
sion levels of Lin28 (left panel) and AR (right panel) were conﬁrmed by RT-
qPCR in total RNAs from xenograft tissues. *P  0.05.
Figure 6 Lin28 enhances expression and activation of the AR. A:
LN-Lin28 and LN-neo cells were transfected with pGL4-AR-Prom-Luc, and
luciferase activities were measured. Activity of the full-length promoter of AR
was increased in Lin28-expressing cells. RT-qPCR assays showing the increase
in AR mRNA expression in Lin28-expressing LNCaP cells. B: Western blot
analysis showing the increase in AR protein expression in LN-Lin28 cells
compared to LN-neo cells. C4-2B cells were transfected with shRNA against
Lin28, and protein expression of AR was analyzed. Down-regulation of Lin28
by shRNA reduced the expression of AR. C: Expression levels of AR target
genes, PSA and NKX3.1, were measured by RT-qPCR in LN-neo and LN-Lin28
cells. mRNA levels of both genes were increased in Lin28-expressing cells
compared to control (Con) cells. D: LN-Lin28 and LN-neo cells were trans-
fected with PSA-E/P-Luc, and luciferase activities were measured. Left panel:
Activation of PSA promoter was enhanced in Lin28-expressing cells compared
to control cells. Right panel: Secretion of PSA by LN-Lin28 and LN-neo cells
withmeasured by ELISA. Levels of PSA secreted by Lin28-expressing cells were
higher than control cells. Data are presented as means  SD of three exper-
iments performed in triplicate. *P 0.05. E: Recruitment of AR to the ARE I/II
and ARE III regions of PSA promoter and ARE inNKX3.1 promoter was analyzed
by chromatin immunoprecipitation assays. Expression of Lin28 enhanced
recruitment of AR to AREs in target gene promoters. IP, immunoprecipitation;
RLU, relative light units.
Lin28 Promotes Growth of CaP CellsThese results were conﬁrmed by Western blot analysis
(Figure 6B). To determine whether down-regulation of
Lin28 affects the expression of AR, we transfected shRNA
against Lin28 into C4-2B cells and analyzed the protein
levels of AR by Western blot analysis. The results showed
that down-regulation of Lin28 led to a decrease in protein
levels of AR (Figure 6B), suggesting that Lin28 expression
is necessary for maintenance of AR expression in CaP cells.
To determine whether Lin28 regulates AR-dependent
signaling, we analyzed the expression levels of PSA and
NKX3.1, two typical AR target genes, in LN-neo and LN-
Lin28 cells by RT-qPCR. The results showed that expres-
sion levels of PSA and NKX3.1 were enhanced in LN-Lin28
cells (Figure 6C). We analyzed the effect of Lin28 on the
transactivating ability of AR using luciferase assays. A
luciferase reporter vector driven by the full-length promoter
of PSA (PSA-E/P-Luc) was transfected into LN-neo and
LN-Lin28 cells, and luciferase assays were performed. The
results showed that Lin28 induced the activity of PSA
promoter (Figure 6D), indicating that Lin28may contribute to
increased transcription of AR-dependent genes by activating
the AR. To conﬁrm these ﬁndings, we analyzed levels of PSA
in supernatants of LN-neo and LN-Lin28 cells by ELISA and
found that secretion of PSA by LN-Lin28 cells was higherThe American Journal of Pathology - ajp.amjpathol.orgcompared to LN-neo cells (Figure 6D).We also examined the
effect of Lin28 on recruitment of AR to the promoters of PSA
andNKX3.1 genes by chromatin immunoprecipitation assays.
The results showed that recruitment of AR to AR-responsive
element (ARE) I/II and ARE III regions in PSA (Figure 6E),
and ARE in NKX3.1 (Figure 6E) promoters, was enhanced293
Tummala et alin Lin28-expressing cells compared to controls. Taken
together, these results demonstrate that Lin28 activates the
AR signaling axis.Discussion
Lin28 is an RNA-binding protein postulated to be overex-
pressed in several malignancies.8,23e26 Lin28 controls the
biogenesis of let-7 miRNAs27,28 and is one of the pluripo-
tency factors that are responsible for the reprogramming of
differentiated cells to stem cell like.29 In this study, we
showed that Lin28 is overexpressed in human CaP com-
pared to benign tissues, promotes growth of human CaP
cells in vitro, and enhances growth of CaP xenografts. To
our knowledge, this is the ﬁrst report demonstrating the role
of Lin28 in CaP cell proliferation and the ability of Lin28 to
promote prostate tumor growth.
Lin28 was originally identiﬁed as a key regulator of
developmental timing in C. elegans.30 It is a conserved
cytoplasmic protein, but on export to the nucleus, regulates
the translation or stability of mRNAs.31 Inmammals, Lin28 is
widely expressed in early development and in stem cells, but
its expression is down-regulated with differentiation and is
absent in most adult tissues.2,32 On the other hand, Lin28 is
up-regulated in human tumors and promotes transformation
and tumor progression.8 Depletion of Lin28 and expression of
let-7 suppress bone metastasis.14 Lin28B, a homologue of
Lin28, is overexpressed in hepatocellular carcinoma, and
exogenous Lin28B promotes cancer cell proliferation.33
Lin28B plays an important role in Myc-dependent cellular
proliferation.34 Several recent reports demonstrated that
Lin28 expression correlates with survival of patients with
malignant diseases.33 In ovarian cancer, patients with high
Lin28B expression had shorter progression-free and overall
survival times than thosewith lowLin28B expression.35 High
Lin28B staining intensity in stage I/II colon cancers correlated
with reduced survival and increased probability of tumor
recurrence.25 A correlation between high expression of Lin28
and Lin28B and poor prognosis of patients with esophageal
cancers was reported.23 Collectively, these reports emphasize
the importance of Lin28 in development and cellular trans-
formation and as a potential oncogene. Our current ﬁndings
that Lin28 promotes CaP growth in vitro and in vivo are in
accordance with the studies described herein and provide
novel evidence for the role of Lin28 in prostate cancer.
We observed strong nuclear staining of Lin28 in benign
prostate tissues almost exclusively in the basal cell layer,
with no staining in the luminal epithelial compartment. This
can be explained by the following: Lin28 is highly expressed
in progenitor cells, and the basal cell compartment is
generally considered to harbor putative prostate stem cells.
Thus, it is conceivable that the benign prostate gland exhibits
high expression of Lin28 in the basal cell layer. An apparent
shift from mostly nuclear localization in benign prostate to
a nuclear þ cytoplasmic or mostly cytoplasmic localization294appears to occur in CaP, which would have to be conﬁrmed
by further studies with a larger sample size.
We have demonstrated increased levels of Lin28 in human
prostate tumors, whichmay likely result from the activation of
c-Myc.36 c-Myc is a known target of let-7 miRNAs and also
a transcriptional target of STAT3 andNF-kB2/p52, which we
have already shown to be constitutively activated in prostate
tumors.22,37 Alternatively, up-regulation of Lin28 in human
CaP may occur due to stabilization of its mRNA owing to
suppression of let-7 miRNAs. Our earlier studies showed that
the double-negative feedback loop between let-7 and Lin28,
encompassing c-Myc, likely plays a major role in prostate
carcinogenesis.6,7 Recent evidence suggests that Lin28
does not rely solely on its regulation of let-7 miRNA bio-
genesis, but also modulates gene expression by altering
translation38,39 and by modulating levels of splicing factors
involved in alternative splicing of mature transcripts.40 Lin28
may regulate expression of prosurvival genes in CaP via one
of these mechanisms. As Lin28 is being increasingly impli-
cated in critical cellular processes, including development,
transformation, and maintenance of stem cell signatures, the
need to fully elucidate its multiple mechanisms of action
becomes urgent to exploit its potential as a therapeutic target
in human CaP.
In summary, we have shown that Lin28 is overexpressed
in prostate carcinomas and promotes prostate tumor growth.
Lin28 also activates AR-dependent signaling and enhances
growth of human CaP cells. These ﬁndings underline the
multifactorial nature of Lin28 and present it as an attractive
target for therapeutic intervention in CaP.
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